

## AEROBIC BACTERIOLOGICAL STUDY IN SURGICAL SITE INFECTIONS WITH SPECIAL REFERENCE TO MRSA, VRSA & VRE

Orhan Pamuk<sup>1</sup>, Kazuo Ishiguro<sup>2</sup>, Isabel Allende<sup>3</sup>

<sup>1</sup> Turkish Novelist and Nobel Laureate in Literature (2006); Professor of Humanities, Columbia University, USA / Istanbul, Turkey

<sup>2</sup> British-Japanese Author and Nobel Laureate in Literature (2017); Alumnus of University of East Anglia; Author of *Never Let Me Go*, United Kingdom

<sup>3</sup> Chilean-American Novelist; Author of *The House of the Spirits*; Member of the American Academy of Arts and Letters; Based in California, USA

### Abstract

#### Keywords:

MRSA, Surgical Site Infections, VRSA.

**Context:** Surgical Site Infections (SSI) has been responsible for the increasing cost, morbidity and mortality related to surgical operations. They continue to be a major problem even in hospitals with most modern facilities and standard protocols of preoperative preparation and antibiotic prophylaxis.

**Aim:** The aim of this study to identify the aerobic bacteriological profile of Surgical Site Infections and its antibiogram, with special reference to Methicillin and Vancomycin resistance patterns of *Staphylococcus aureus* and *Enterococci* in this area.

**Settings and Design:** This is a prospective study carried out in the Department of Microbiology for one and half year at Siddhartha Medical College/Government General Hospital, Vijayawada, Andhra Pradesh, India.

**Methods:** Specimens were collected from those post operative wounds which were showing signs/symptoms of an infection during the stay of the patient's in the hospital and also during their follow up visits to the outpatient department after their discharge from the hospital according to CDC guidelines. All the specimens collected were transported immediately to the laboratory for further processing according to standard protocols.

**Results:** The prevalence of SSI is 8.94% (136 out of 1520 surgeries). Out of 136 clinically diagnosed SSIs, 113 organisms isolated. Out of 113 organisms, *Staphylococcus aureus* (28.31%) was the most predominant organism followed by *Pseudomonas aeruginosa* (17.69%). Among 32 strains of *Staphylococcus aureus*, 11(34.3%) MRSA and 1(3.12%) strain of VISA were detected.

**Conclusion:** An effective national and state level antibiotic policy and draft guidelines should be introduced to preserve the effectiveness of antibiotics and for better patient management.

### Introduction

A major 30% - 50% of antimicrobials prescribed in hospital practice are for surgical prophylaxis to prevent post-operative wound infection. A reduction in the infection rate to a minimum level could have significant benefits in terms of both patient comfort and medical resources used.<sup>[1]</sup>

The common pathogenic bacteria in SSIs include *Staphylococci*, *Pseudomonas species*, *Streptococci*, *Enterococci*, *Esch.coli*, *Klebsiella*, *Enterobacter*, *Citrobacter*, *Acinetobacter*, *Proteus*, etc.,<sup>[2][3]</sup>

*Staphylococcus aureus* is the commonest cause of SSI. An increased number of Methicillin Resistant *Staphylococcus aureus* (MRSA) strains have been seen worldwide.<sup>[3]</sup>

*Enterococci* emergence in the past two decades is in many respects attributable to their resistance to many commonly used antimicrobial agents and ease with which they appear to attain and transfer resistant genes,<sup>[4]</sup> thus giving rise to *Enterococci* with High-Level Aminoglycoside Resistance (HLAR) and glycopeptide resistance.

Data regarding Surgical Site Infections and its etiology, diagnostic criteria and treatment options are lacking in this region, hence the present study was undertaken to identify the aerobic bacteriological profile of Surgical Site Infections and its antibiogram.

## Materials and Methods

This is a prospective study carried out in the Department of Microbiology, Siddhartha Medical College/Government General Hospital, Vijayawada, Andhra Pradesh, India for one and half year. Study includes 136 clinical specimens from patients who have developed Surgical Site Infections. The present study was taken up after the review and approval by the institutional ethical committee.

An informed oral consent was taken from the patients or their attendants.

### Inclusion criteria

Patients underwent clean and clean-contaminated surgeries electively; contaminated and dirty surgeries on emergency basis.

### Exclusion criteria

1. Wound site pre operatively infected will be excluded
2. Burn injuries and donor sites of split skin grafts.
3. Patients undergoing re-operations

Specimens were collected from those post operative wounds which were showing signs/symptoms of an infection during the patients stay in the hospital and also during their follow up visits to the outpatient department after their discharge from the hospital according to CDC guidelines [5].

All the specimens collected were transported immediately to the laboratory for further processing.

The samples collected were processed as follows [6]:

- a) Direct microscopic examination of gram stained smear.
- b) Inoculation of the samples onto different culture media for specific aerobic organisms and incubated for 24 hours at 37°C.
- c) Recognition of colonies followed by Identification of bacteria
- e) Antibiotic sensitivity testing which includes as per CLSI guidelines:
  - a. Kirby-Bauer Disk Diffusion test using HiMedia Laboratories products, Mumbai, India.
  - b. Detection of MRSA, VRSA, VRE
  - c. E-test – Vancomycin/Cefoxitin Dual strip by HiMedia Laboratories, Mumbai, India.
  - d. Agar Screening and Agar Dilution methods – Vancomycin powder by Himedia Laboratories, Mumbai, India.
  - e. Detection of Beta lactamases using HiMedia antibiotic discs

### Sample Size Calculation:

$$N = p(1-p)(Z_{\alpha/2}/\epsilon)^2$$

N=Sample size

P=Prevalence rate in %

Z=Confidence interval of 95% which is equivalent to confidence of 1.96

E= Error.

### Statistical Analysis:

All the data were entered into spread excel sheet and analyzed. All Quantitative descriptive variables were expressed as number, percentages. Statistical analysis was assessed by Graph pad software. The p value <0.05 is considered as significant.

## Results

The prevalence of SSI is 8.94% (136/1520). Of the 136 clinically diagnosed cases of SSI, 59 (43.3%) cases belonged to class I wound, 39 (28.6%) to class II, 32 (23.5%) to class III and 6 (4.41%) cases belonged to class IV wounds. In present study, 119 (87.5%) of 136 cases of SSI were diagnosed between 3rd and 8th postoperative day. 79 (58.08%) cases were diagnosed between 5th and 8th day with the peak on 5th day. Out of 136 cases of SSI, 28 (20.58%) patients had diabetes, 16 (11.76%) patients were smokers, 7 (5.14%) patients had diabetes and were smokers and postoperative drain was used on 15 (11.02%) patients.

Out of 136 clinically diagnosed cases of SSI, 95 (69.8%) were males and 41 (30.14%) were females with a male to female ratio of 2.37: 1. Maximum number of SSI patients was in the age group of 31-40 years followed by age group of 21-30 years (Table 1).

**Table No. 1 Age and Sex distribution of patients with SSI**

Sl.No. S.No.	Age Group in Years	Male			Female			Total	
		Clinical y Diagnose d	Cultur e positiv e	% of culture positiv e	Clinical y Diagnose d	Cultur e positiv e	% of culture positive	No	%
1.	0-10	5	3	2.20	2	1	0.73	7	5.14
2.	11-20	14	8	5.88	3	1	0.73	17	12.5
3.	21-30	16	16	11.7	9	7	5.14	25	18.3
4.	31-40	23	20	14.7	7	8	5.88	30	22.0
5.	41-50	15	11	8.08	7	5	3.67	22	16.1
6.	51-60	13	9	6.61	8	5	3.67	21	15.4
7.	61 and above	9	7	5.14	5	4	2.94	14	10.2
Total		95	75	55.1	41	28	20.5	103	100

Of the 136 clinically diagnosed cases of SSI, 103 (75.73%) samples were culture positive and 33 (24.26%) samples yielded no growth.

In the present study of 136 samples, 95 (69.85%) of positive Gram stained smears developed growth on culture and 6(4.41%) samples yielded no growth. Among the negative Gram stained smears, 8 (5.88%) were culture positive and 27(19.85%) were culture negative. At P=0.05 and df =1, the Chi Square value obtained as 76.5, it was significant (Table 2).

**Table No.2 - Direct microscopy and culture positivity**


Sl.No.	Gram Stain		Positive culture	Negative culture	Total
1	Positive	PC & GPC	31	2	101
		PC & GNB	54	4	
		PC, GPC & GNB	10	0	

2	Negative	Few PC, No Org	8	10	35
		No PC, No Org	0	17	
Total			103	33	136

SSI were more common in Contaminated and dirty wounds with percentages 93.7% and 100% respectively than in clean (55.9%) and clean contaminated (87.1%) wounds.

In this study, a total of 113 organisms isolated among these, 103 (91.1%) samples yielded a single organism on culture and 10 (8.8%) samples yielded 2 organisms (mixed). Out of 113 Culture positive samples, *Staphylococcus aureus* (28.31%) was the most predominant organism followed by *Pseudomonas aeruginosa* (17.69%) which, in turn followed by *Escherichia coli* (13.27%) and *Klebsiella pneumoniae* (11.50%) (Chart 1).

Chart 1. Types of aerobic bacteria isolated



*Staphylococcus aureus* (36.3%), was the most common organism isolated from class I wound infection, followed by *Pseudomonas aeruginosa* (15.1%). *Pseudomonas aeruginosa* (20.5%) was the predominant organism isolated from class II wound infection. The most common organism isolated from class III and IV wound infection was *Staphylococcus aureus* 26.6% and 50% respectively.

50% of gram negative isolates have shown susceptibility to Imipenem, Gentamicin, Amikacin, Tetracycline, Cotrimoxazole, Ceftriaxone, Ceftazidime, Ceftazidime/Clavulanic acid (Table 3).

Table 3. Sensitivity pattern of Gram Negative isolates

Organisms	AMX	PIT	CTX	CAZ	CAC	TE	COT	CIP	AK	GEN	IPM
	S(%)	S(%)	S(%)	S(%)	S(%)	S(%)	S(%)	S(%)	S(%)	S(%)	S(%)
<i>Ps.aeruginosa</i> (n=20)	0(0)	16(80)	-	9(45)	11(55)	13(65)	11(55)	8(40)	13(65)	15(75)	16(80)

Esch.coli (n=15)	2(13.3)	-	8(53.3)	9(60)	8(53.3)	10(66.6)	8(53.3)	6(40)	8(53.3)	8(53.3)	15(100)
K.pneumoniae (n=13)	3(23.07)	-	7(53.8)	8(61.5)	7(53.8)	9(69.2)	7(53.8)	5(38.4)	9(69.2)	10(76.9)	13(100)
Pr.mirabilis (n=9)	1(11.1)	-	3(33.3)	6(66.6)	5(55.5)	6(66.6)	3(33.3)	2(22.2)	5(55.5)	6(66.6)	9(99.9)
C.koseri (n=3)	0	-	2(66.6)	2(66.6)	2(66.6)	2(66.6)	2(66.6)	1(33.3)	3(100)	3(100)	3(100)
Prov.retti (n=2)	0	-	1(50)	1(50)	1(50)	1(50)	2(100)	2(100)	1(50)	2(100)	2(100)
Acinetobacter (n=2)	0	1(50)	-	0	1(50)	2(100)	2(100)	1(50)	2(100)	2(100)	2(100)
Total = 64	6(9.3)	58 (90.6)	21 (32.8)	35 (54.6)	35 (54.6)	43 (67.1)	35 (54.6)	25 (39.06)	41 (64.06)	46 (71.8)	55 (85.9)

(AMX-Amoxycillin, PIT-Piperacillin/Tazobactam, CTX-Cefotaxime, CAC-Ceftazidime/ Clavulanic acid, TE-Tetracycline, COT-Cotrimoxazole, CIP-Ciprofloxacin, AK-Amikacin, GEN-Gentamicin, IPM-Imipenem).

50% of gram positive isolates have shown susceptibility to vancomycin, Linezolid, Gentamicin, Levofloxacin, Azithromycin, Clindamycin, Erythromycin, Amoxyclav (Table 4).

**Table 4. Sensitivity pattern of Gram Positive isolates**

Organisms	P	AMC	CN	CL	E	AZM	TE	COT	LE	GEN	LZ	VA
	S(%)	S(%)	S(%)	S(%)	S(%)	S(%)	S(%)	S(%)	S(%)	S(%)	S(%)	S(%)
S.aureus (n=32)	3(9.3)	21(65.6)	21(65.6)	23(71.8)	18(56.2)	21(65.6)	12(37.5)	11(34.3)	18(56.2)	18(56.2)	31(96.8)	32(100)
S.epidermidis (n=7)	0	1(14.2)	7(100)	5(71.4)	6(85.7)	6(85.7)	5(71.4)	5(71.4)	4(57.1)	6(85.7)	7(100)	7(100)
E.faecalis (n=5)	1(20)	3(60)	-	2(40)	2(40)	3(60)	2(40)	2(40)	2(40)	4(80)	5(100)	5(100)
Str.pyogenes (n=5)	3(60)	4(80)	3(60)	3(60)	4(80)	4(80)	3(60)	3(60)	4(80)	5(100)	5(100)	5(100)
Total = 49	7 (14.2)	29 (59.1)	28 (57.1)	33 (67.3)	30 (61.2)	34 (69.3)	22 (44.8)	21 (42.8)	28 (57.1)	33 (67.3)	48 (97.9)	49 (100)

(P-Penicillin, AMC-Amoxyclav, CN-Cefoxitin, CL-Clindamycin, E-Erythromycin, AZM Azithromycin, TE-Tetracycline, COT-Cotrimoxazole, LE-Levofloxacin, GEN-Gentamicin, LZ-Linezolid, VA- Vancomycin).

Out of 32 Staphylococcal strains, 4(12.5%) were constitutive MLSB (Macrolide-Lincosamide-Streptogramin B) resistant, 5(15.6%) were inducible MLSB resistant (inducible clindamycin resistant) and 5(15.6%) belonged to MS phenotype. 18(56.25%) strains were susceptible to both erythromycin and clindamycin.

In our study, among 32 strains of *Staphylococcus aureus*, 10 (31.2%) strains were methicillin resistant by cefoxitin disc diffusion test and 11 (34.3%) by cefoxitin E-test (Fig 1). 50% of MRSA isolates shown susceptibility to Vancomycin, linezolid, gentamicin, levofloxacin, azithromycin, erythromycin, clindamycin (Table 5).




**Fig 1. Combined vancomycin & cefoxitin E test strips testing of *S.aureus* isolates**


**Table 5. Sensitivity pattern of MRSA and MSSA isolates**

Organisms	P	AMC	CN	CL	E	AZM	TE	COT	LE	GEN	LZ	VA
	S(%)	S(%)	S(%)	S(%)	S(%)	S(%)	S(%)	S(%)	S(%)	S(%)	S(%)	S(%)
MRSA (n=11)	0(0)	0(0)	0(0)	6(54.5)	7(63.6)	7(63.6)	4(36.3)	4(36.3)	8(72.7)	8(72.7)	10(90.9)	11(100)
MSSA (n=21)	3(14.2)	15(71.4)	21(100)	11(52.3)	11(52.3)	14(66.6)	8(38.1)	7(33.3)	10(47.6)	10(47.6)	21(100)	21(100)
Total = 32	3(9.3)	15(46.8)	21(65.6)	17(53.1)	18(56.2)	21(37.5)	12(37.5)	11(34.3)	18(56.2)	18(56.2)	31(96.8)	32(100)

Out of 32 Staphylococcal strains, Only 1(3.12%) strain was shown growth in 4ug/ml vancomycin Muller Hinton Agar plate, considered Vancomycin Intermediate Staphylococcus aureus, it was also MRSA and remaining strains are all sensitive to vancomycin by all methods (Fig 2, 3 & 4).



*Fig 2. Agar Screening Method*



*Fig 3. Agar Dilution Method*

All 5 strains of *Enterococcus faecalis* were sensitive to vancomycin detected by vancomycin disk diffusion method, Agar screening, Agar dilution method and E- test strips.



**Fig 4. Showing VISA by Agar Dilution Method**

## Discussion

Surgical Site Infection (SSI) continues to be a major problem even in hospitals with most modern facilities and standard protocols of preoperative preparation and antibiotic prophylaxis<sup>[1]</sup>. SSIs are usually caused by the exogenous and endogenous microorganism that enters the operative wound during the course of the surgery<sup>[2]</sup>.

The present generations of surgeon has seen increasing numbers of serious infections related to a complex combination of factors, including the performance of more complicated and longer operations; an increase in number of geriatric patients with accompanying chronic or debilitating diseases; many new surgical procedures with implants of foreign materials; a rapidly expanding number of organ transplants requiring the use of immunosuppressive agents; and increased use of diagnostic and treatment modalities that cause bacterial exposures or the suppression of normal host resistance.

Surgical Site infections were confirmed by bacteriological study, the overall infection rate was 6.77% as per this study (Table 6).

**Table 6. Incidence of SSI by various studies**

Author	Year	Country	Infection Rate
Lilani SP [9]	2005	India	8.95%
Rafael Lima Rodrigues de Carvalho et al [11]	2011	Brazil	3.4%
Narasinga rao Bandaru [12]	2012	India	9.81%
Farhan Sattar et al [13]	2016	Pakistan	33.68%
Marie Josee Mukagendaneza et al [14]	2018	Rwanda	10.9%
Present Study	2014	India	6.77%

Lilani SP *et al*<sup>[7]</sup> described that Surgical site infections are the third most commonly reported nosocomial infection and they account for approximately a quarter of all nosocomial infections.



This correlates with the study by Chia JYH *et al*<sup>[12]</sup> in which 64% of the cases were diagnosed between the 5th and 8th postoperative day. Lilani SP *et al*<sup>[7]</sup> observed that mean postoperative stay in patients who developed infections were almost four times (24.82 days) as compared to patients who did not develop SSI where the mean postoperative stay was 6.19 days.

In another study in Pune, there was a marginal preponderance of male patients developing SSI (7.4%) over female patients with SSI (5.1%)<sup>[13]</sup>. In contrast in Aligarh, females (27%) showed preponderance of SSI than males (18%)<sup>[14]</sup>. Similar findings were demonstrated by Mead *et al*<sup>[15]</sup>, who observed an increased Clean wound infection in patients less than 1 year old (2.7%) or greater than 50 years old (2.8%) versus those 1 to 50 years old (0.7%). Narasinga rao Bandaru *et al*<sup>[9]</sup> observed that age of more than 50 years was found to be at risk factor for the postoperative wound infection.

This correlates with a study by Lilani SP *et al*<sup>[7]</sup>, in which 14 (82.36%) out of 17 cases of SSI were culture positive and 3 (17.64%) were culture negative. In a study conducted by Similarly, out of 52 samples studied by Kownhar H *et al*<sup>[16]</sup>, 46 (88.46%) were culture positive and 6 (11.54%) samples yielded no growth. Culture negativity may be due to antibiotic therapy prior to culture of material from an apparently infected site or due to the presence of fastidious or atypical organisms that do not grow on standard culture media or grow so slowly that plates are discarded before growth is apparent.

*Staphylococcus* is predominant pathogen in Surgical site Infection from many years. It may be due to presence of more Staphylococcal carriers among hospital staff who could be silent carriers or due to strong Virulence factors of *Staphylococci* and also emergence of Multidrug resistant staphylococci like MRSA.

Studies of previous years (before 1990) shown that *Escherichia coli* was second most predominant pathogen but Studies from 1990 onwards shown that *Pseudomonas aeruginosa* was the second most predominant. This may be due to fact that *Pseudomonas* is an emerging pathogen in hospital acquired infections & also in procedures where most sophisticated device are using (Table 7).

**Table 7. Prevalence of Bacterial isolates of various studies from surgical site infections**

Organism	Edwards et al <sup>22</sup> (1976)	Udgaonkar <sup>23</sup> (1986)	Kownhar et al <sup>21</sup> (2008)	Gayathreenaik et al <sup>24</sup> (2011)	Setty NH et al <sup>25</sup> (2014)	Maire Josee M et al <sup>14</sup> (2018)	Present study
<i>S.aureus</i>	30.3%	28.13%	37%	32.2%	55.5%	6%	28.31%
<i>S.epidermidis</i>	21.5%	22.16%	-	1.48%	-	3%	6.19%
<i>Enterococcus</i>	22.6%	0.6%	03%	1.6%	-	-	4.4%
<i>Group A Beta hemolytic Streptococcus</i>	-	1.01%	-	1.9%	-	-	4.4%
<i>Pseudomonas aeruginosa</i>	13.8%	13.36%	37%	12.8%	36.11%	-	17.69%
<i>Escherichia coli</i>	27.8%	21.25%	4.8%	8.9%	16.67%	15%	13.27%
<i>Klebsiella pneumoniae</i>	11.75%	14.71%	8.0%	4.7%	27.78%	55%	11.50%
<i>Proteus vulgaris</i>	-	16.59%	4.8%	2.7%	-	-	-
<i>Proteus mirabilis</i>	9.2%	-	-	1.6%	13.89%	12%	7.9%

<i>Citrobacter freundii</i>	-	1.16%	1.6%	2.3%	16.67%	-	2.65%
<i>Enterobacter aerogenes</i>	4.9%	-	-	1.2%	-	-	-
<i>Acinetobacter</i>	-	-	3.2%	5.8%	-	9%	1.76%

According to Goswami NN *et al*<sup>[21]</sup> *Pseudomonas aeruginosa* were sensitive to ciprofloxacin (83.78%), gatifloxacin (51.35%), and meropenem (51.35%). *Escherichia coli* was sensitive to levofloxacin (72.41%) and ciprofloxacin (62.07%). *Klebsiella pneumoniae* was sensitive to ciprofloxacin (63.16%), levofloxacin (63.16%), gatifloxacin (63.16%), and linezolid (56.52%). *Proteus mirabilis* was sensitive to ciprofloxacin (75%) and linezolid (62.50). *Proteus vulgaris* was sensitive to ampicillin+sulbactam (57.14%) followed by levofloxacin (50%). As per their work Linezolid showing sensitivity against Gram negative bacteria. *Escherichia coli* and *Klebsiella pneumoniae* showed sensitivity to ciprofloxacin in similar to the present study. For *Pseudomonas aeruginosa* they used meropenem, observed more resistant where as in the present study Imipenem was used, the resistance rate is slightly lower. Due to some difficulties Meropenem, Etrapeenem and Linezolid were not used in the present study. From different studies there is an emergence of meropenem, and third generation cephalosporin resistant *Pseudomonas aeruginosa*. In contrast to present study Lilani SP *et al*<sup>[7]</sup>, reported that *Pseudomonas aeruginosa* exhibited 100% resistance to gentamycin. Other Gram negative bacilli were found to be 100% resistant to tetracycline followed by ampicillin (83.33%).

In line with this study Gayathree naik *et al*<sup>[19]</sup> reported that out of the 83 *Staphylococcus aureus* isolates, Penicillin Sensitivity was seen in 7 (12.3%), Erythromycin sensitivity was seen in 36 (43.4%), Ciprofloxacin sensitivity was seen in 38 (45.8%), Cotrimoxazole sensitivity was seen in 58 (69.9%), Cefaperazone sensitivity was seen in 53 (66.3%), Netillin sensitivity was seen in 63 (75.9%) and Oxacillin sensitivity seen in 75 (90.4%) respectively. All the 83 (100%) isolates were sensitive to Vancomycin. Goswami NN *et al*<sup>[21]</sup> reported that *S. aureus* was sensitive to Rifampicin (89.58%), levofloxacin (60.42%), and Vancomycin (54.17%).

Joyce SB *et al*<sup>[22]</sup> also observed a high percentage of Penicillin resistance among strains of *Staphylococcus aureus* (91%) and *Enterococcus faecalis* (100%) causing SSI. 73% of the *Staphylococcus aureus* strains were resistant to Cotrimoxazole, 51% were resistant to ciprofloxacin and 11% of the strains were resistant to Gentamicin and Amikacin. *Pseudomonas aeruginosa* was resistant to Cotrimoxazole (94%), followed by 103 Ciprofloxacin (58%), Gentamicin (15%) and Amikacin (9%).

The Prevalence of MRSA has varied from hospital to hospital in various countries. The incidence of MRSA in India ranges from 30-70%<sup>[23]</sup>. This wide range of MRSA prevalence rate is extremely difficult to explain these conflicting data with regards to both time and place of study, the variation is probably due to Differential clonal expansion and drug pressure in the community (**Table 8**).

**Table 8. Rate of isolation of MRSA & MSSA among SSI in different study groups**

S.No	Author	Year	MSSA	MRSA
2	Kownhar H <i>et al</i> <sup>21</sup>	2008	79.3%	21.7%
4	Bhattacharya S <sup>31</sup>	2012	74.55%	25.45%
5	Ranjan KP <sup>32</sup>	2013	72.04%	27.96%
6	Present study	2014	65.62%	34.37%

Gayathree naik *et al*<sup>[19]</sup> reported that the MRSA strains (100%) were sensitive to Vancomycin, Rifampicin, Teicoplanin, Linezolid, this finding is line with present study.

Bhattacharya S *et al*<sup>[24]</sup> stated that the MRSA strains have been found to be 100% sensitive to linezolid and tigecycline followed by fucidin (92.51%), mupirocin (88.39%), levofloxacin (75.66%) and doxycycline (72.28%). No vancomycin resistant strains were detected, but 3 strains (1.12%) were found to be intermediately susceptible to it (VISA).

Flannery EL *et al*<sup>[26]</sup> from university of Michigan, USA described that because cocolonization with MRSA and VRE precedes VRSA development, MRSA/VRE cocolonization in the device group occurred most frequently in wounds (4.1 per 100 resident-months).

Antony SJ *et al*<sup>[27]</sup> from university school of medicine, Texas given that case series describing an outbreak of VRSA/VISA associated infections in orthopedic related procedures that occurred on a medical mission trip in Antigua, Guatemala.

Furthermore, Extensive use of vancomycin creates a selective pressure that favors the outgrowth of rare, vancomycin-resistant clones leading to heterogenous vancomycin intermediate *S. aureus* (hVISA) clones, and eventually, with continued exposure, to a uniform population of vancomycin-intermediate *S. aureus* (VISA) clones. These heterogeneous VISA (hVISA) are more common; reports from around the world indicate that 0.5%–20% of MRSA are heteroresistant<sup>[28]</sup>. Currently, no standardized method for identifying hVISA exists. Population analysis profiling (PAP) has been proposed as the most precise method of determining heteroresistance. The present study didn't mention about hVISA because of few difficulties like could not get Control strain -MU and also PAP method is a gold standard for detection of hVISA. There are no much reports about VRSA/VISA in south India related to Surgical Site infections. Regarding Vancomycin Resistant Enterococci only 5 *Enterococci* strains were isolated out of 136 samples. For which Vancomycin resistant was studied by using all the four, methods and found them to be sensitive to Vancomycin. Still the sample size is too low and VRE has to be studied further.

VRSA should be cautiously interpreted as this might be because of false positive result by bacteria like acinetobacter<sup>[29]</sup> and the resistance to vancomycin was not counterchecked by other laboratory.

## Conclusion

From this study we conclude that MRSA are the commonest etiological agents of Surgical Site infections. Emergence of MRSA, VRSA and Beta lactamase producers like *Pseudomonas spp*, *Escherichia spp*, *Klebsiella spp*, added more severity to this clinical condition. Regular antimicrobial susceptibility surveillance is essential for area-wise monitoring of the resistance patterns. An effective national and state level antibiotic policy and draft guidelines should be introduced to preserve the effectiveness of antibiotics and for better patient management.

There should be a policy of mandatory infection control practices in every hospital, surveillance of HCWs and patients and also there is a need to emphasize the rational use of antimicrobials and strictly adhere to the concept of "reserve drugs" to minimize the misuse of available antimicrobials.

## Acknowledgements

I express my sincere and deep gratitude to all authors and guides whose research works helped me in doing this study. I would like to thank clinicians for their advice, willing help and spending precious time throughout the course.

## References

1. Nandi PL, Rajan SS, Mak KC, Chan SC, So YP, "Surgical wound infection", in *HKMJ*, Vol. 5, pp. 82-6, 1999.
1. Nichols RL, "Current strategies for Prevention of Surgical Site Infections", in *Curr Infect Dis Rep*, Vol. 6, No. 6, pp. 426-434, Dec 2004.
2. Mangram AJ, Horan TC, Pearson ML, Silver LC, Jarvis WR, "Guidelines for prevention of surgical site infection, 1999, Criteria for defining SSIs. The Hospital Infection Control Practices Advisory Committee" in *Infection Control and Hospital Epidemiology*, vol 20, n. 4, pp. 24, 1999.
3. Forbes BA, Sahm DF, Weissfeld AS, "Bailey & Scott's Diagnostic Microbiology", 10th ed, St. Louis: Mosby, 1998.

4. Centers for Disease Control and Prevention, SSI, Guideline for prevention of Surgical Site Infection, 2017. <https://www.cdc.gov/infectioncontrol/guidelines/ssi/index.html>
5. CLSI. *Performance Standards for Antimicrobial Susceptibility Testing; Twenty-First Informational Supplement*, CLSI document M100-S21, Wayne, PA: Clinical and Laboratory Standards Institute, 2011.
6. Lilani SP, Jangale N, Chowdhary A, Daver GB, “Surgical site infection in clean and clean- contaminated cases,” in *Indian J Med Microbiol*, vol 23, issue 4, pp. 249-52, 2005.
7. Rafael Lima Rodrigues de Carvalho, Camila Claudia Campos, Lucia Maciel de Castro Franco, Adelaide De Mattia Rocha and Flavia Falci Ercole, “ Incidence and risk factors for surgical site infection in general surgeries”, in *Rev Lat Am Enfermagem*, vol 5, 2017, e2848.
8. Narasinga Rao Bandaru, Ranga Rao A, Vijayananda Prasad K, Rama Murthy DVSS, “A Prospective Study of Postoperative Wound Infections in a Teaching Hospital of Rural Setup”, in *Journal of Clinical and Diagnostic Research*, vol 6, issue 7, pp 126—1271, 2012.
10. Farhan Sattar, Zeeshan Sattar, Mohsin Zaman and Shahzad Akbar, “Frequency of Post operative Surgical site infections in a tertiary care hospital in Abbottabad, Pakistan”, in *Cureus*, vol 11, issue 3, 2019 Mar, e43243.
9. Marie Josee Mukagendaneza, Emmanuel Munyaneza, Esperance Muhawenayo, Dancilla Nyirasebura, Egide Abahuje, John Nyirigira, et al, “ Incidence, root causes and outcomes of surgical site infections in a tertiary care hospital in Rwanda: a prospective observational cohort study”, in *Patient Safety in Surgery*, vol 13, issue 10, 2019.
10. Chia JYH, Tan KW, Tay L, “A survey of postoperative wound infections in obstetrics and gynaecology- The Kandang Kerbau hospital experience”, *Singapore Med J*, vol 34, pp. 221-4, 1993.
11. Varsha S, Saikat B, Upendra L, “Surgical site infections: A one year prospective study in a tertiary care center. *Int J Health Sci (Qassim)*”, vol 6, pp 79-84, 2012.
12. Khan MA, Ansari MN, Bano S, “Post operative wound infection”, in *Indian J Surg*, vol 48, pp 383-6, 1985.
13. Mead PB, Pories SE, Hall P, “Decreasing the incidence of surgical wound infections”, in *Arch Surg*, vol 121, pp 458, 1986.
14. Kownhar H, Shankar EM, Vignesh R, Sekar R, Velu V, Rao VA, “High isolation rate of *Staphylococcus aureus* from surgical site infections in an Indian hospital” in *J Antimicrob Chemother*, vol 61, no 3, pp 758-60, 2008.
15. Edwards LD, “The Epidemiology of 2056 Remote Site Infections and 1966 *Surgical Wound Infections occurring in 1865 patients*”, in *Annals of Surg*, vol 184, pp 758-66, 1976.
16. Udgaonkar, Bhavthanker A, “Bacteriological study of Postoperative wound infections”, in *JIMA*, vol 83, pp 231-35, 1985.
17. Gayathree Naik, Srinivas R Deshpande, “A Study on Surgical Site Infections Caused by *Staphylococcus Aureus* with a special search for Methicillin-Resistant isolates”, in *Journal of Clinical and Diagnostic Research*, vol 5, no 3, pp 502-508, June 2011.
18. Setty NH, Nagaraja MS, Nagappa DH, Giriyaiah CS, Gowda NR, Laxmipathy Naik RD, “A study on Surgical Site Infections (SSI) and associated factors in a government tertiary care teaching hospital in Mysore, Karnataka”, in *Int J Med Public Health*, vol 4, pp 171-5, 2014.
19. Goswami NN, Trivedi HR, Goswami AP, Patel TK, Tripathi CB, “Antibiotic sensitivity profile of bacterial pathogens in postoperative wound infections at a tertiary care hospital in Gujarat, India”, in *J Pharmacol Pharmacother*, vol 2, no 158-64, 2011.
20. Joyce SB, Lakshmi Devi N, “Surgical site infections. Assessing risk factors, outcomes and antimicrobial sensitivity patterns”, in *Afr J Microbiol Res*, vol 3, no 4, pp 175-9, 2009.
21. Bratzler DW, Hunt DR, “The surgical infection prevention and surgical care improvement projects: national initiatives to improve outcomes for patients having surgery”, in *Clin Infect Dis*, vol 43, pp 322-330, 2006.
22. Bhattacharya S, Pal K, Jain S, Chatterjee SS, Konar J, “Surgical Site Infection by Methicillin Resistant *Staphylococcus aureus* – on Decline?”, in *J Clin Diagn Res*, vol 10, no 9, pp 2016 Sep;10(9):DC32-DC36.
23. Ranjan KP, Neelima Ranjan, Shashi Gandhi, “Surgical site infections with special reference to methicillin resistant *Staphylococcus aureus*: experience from a tertiary care referral hospital in North India”, in *IJRMS*, Vol 1, no 2, 2013.
24. Flannery EL, Wang L, Zöllner S, Foxman B, Mobley HL, Mody L, “Wounds, functional disability, and indwelling devices are associated with cocolonization by methicillin-resistant *Staphylococcus aureus* and vancomycin-resistant enterococci in southeast Michigan”, in *Clin Infect Dis*, vol 53, no 12, pp 1215-22, Dec 2011.

25. Antony SJ, “Case Series Describing an Outbreak of Highly Resistant Vancomycin Staphylococcus aureus (Possible VISA/VRSA) Infections in Orthopedic Related Procedures in Guatemala”, *Drug Targets*, vol 14, no 1, pp 44-8, 2014.
26. Robin A Howe, Alastair Monk, Mandy Wootton, Timothy R Walsh, Mark C Enright, “Vancomycin Susceptibility within Methicillin-resistant Staphylococcus aureus Lineages”, *Emerg Infect Dis*, vol 10, no 5, May 2004.
27. Hemant Singhal, Kanchan Kaur, “Wound infection. Overview: History. The ancient Egyptians were the first civilization to have trained clinicians to treat physical ailments, in *Surg Infect (Larchmt)*, vol 10, pp 323-31, 2009